Navigation Links
Danbury Hospital Researchers On Track Developing Tool For More Precise Diagnosis Of Gynecologic Cancers
Date:11/14/2019

A promising new non-invasive diagnostic tool designed to detect women’s cancers, even at the earliest stages of disease development or their recurrence, is attracting interest and attention.

Researchers at Danbury Hospital’s Rudy L. Ruggles Biomedical Research Institute (Ruggles Research Institute), now part of Nuvance Health, and the Icahn School of Medicine at Mount Sinai have shown that an early detection tool for gynecological cancers, developed by the team, may also be used to determine whether chemotherapy and other invasive treatments are required for patients following an initial diagnosis. According to a just published study in the journal Cold Spring Harbor Molecular Case Studies, researchers believe that circulating tumor DNA (ctDNA) biomarkers can provide an additional source of information that could help avoid both misdiagnoses and prevent overtreatment.

Ovarian cancer is among the most lethal cancers, with 70 percent of women experiencing a recurrence of the disease within 18 months. This poor outcome often follows a grueling treatment regimen which can include surgeries, multiple rounds of platinum-based chemotherapy, radiation, CT and PET scans, biopsies, blood draws and other tests and treatments that affect patients’ physical and emotional health, well-being and quality of life.

Often described as a “silent killer,” the majority of women are diagnosed at the later stages of the disease. Further, diagnosing ovarian cancer presents unique challenges for physicians as symptoms are often non-specific, such as abdominal bloating, indigestion, changes in appetite, and back pain. Researchers from the Ruggles Research Institute and the Icahn School of Medicine at Mount Sinai believe that liquid biopsy, using personalized ctDNA biomarkers based on an individual’s specific tumor genetic “signature,” would lead to greater diagnostic accuracy.

The case study focused on a patient who initially presented with an unexplained whole-body rash and multiple uninformative dermatologic examinations, biopsies and treatments which eventually led to a diagnosis of ovarian cancer and surgery. Within a day following her debulking surgery, the rash — which the patient had endured over a three-month period — resolved. The patient received chemotherapy and she was clinically diagnosed as cancer free. Surprisingly and unexpectedly, one year later the rash reappeared, prompting speculation of tumor recurrence and a concern to initiate aggressive secondary treatment. However, the gynecologic oncology research team sought to use cutting-edge molecular techniques to better examine if her cancer had truly recurred. Using genomics-based testing and bio-banked tumor and blood samples which had been stored from the patient throughout the course of her care, researchers developed exquisitely sensitive and patient-specific ctDNA biomarkers which could detect even traces of her cancer if they were present in her bloodstream. Using these markers, they could demonstrate that no traces of cancer were detectable despite the presence of the patient’s unexplained rash. No additional treatment or chemotherapy would be prescribed. Now, two years after the patient’s original surgery, and with additional negative ctDNA findings, the patient remains healthy with no evidence of disease recurrence.

According to Dr. John Martignetti, Director of the Laboratory for Translational Research at the Ruggles Biomedical Research Institute and an expert in human genetics and genomic sciences who led the research team, these results from a preliminary single-case study are encouraging.

“The use of liquid biopsy and ctDNA is a promising tool designed to improve diagnostic, prognostic and predictive values in many types of tumors,” he said, “Based on these results, as well as our longitudinal precision medicine study which includes biobanking of tumor and blood samples from our patients, we believe that ctDNA could be a powerful tool for not only helping to detect disease earlier but just as importantly, to provide information and clarity on when additional treatment is not needed.”

Catch up on the latest news at Danbury Hospital.

CONTACT
Amy Forni
Manager, Public Relations
203-739-7478
Amy.Forni@nuvancehealth.org

Andrea Rynn
Director, Public & Government Relations
203-739-7919
Andrea.Rynn@nuvancehealth.org

About John Martignetti, MD, PhD
The Rudy L. Ruggles Biomedical Research Institute’s Laboratory for Translational Medicine is headed by Dr. John Martignetti. He has assembled a research group here at the institute and with his clinical and research colleagues here and at the Mount Sinai Health System has established a state-of-the-art precision medicine program linking gynecologic/oncology patient clinical care and genomic information to improve treatment and surveillance.

About the Rudy L. Ruggles Biomedical Research Institute
Rudy L. Ruggles Biomedical Research Institute at Western Connecticut Health Network, now part of Nuvance Health, aims at advancing the health of our community by performing innovative translational research with the goal of improving the current standard of patient care. The Rudy L. Ruggles Biomedical Research Institute includes a team of renowned scientists known for their groundbreaking work and expertise in various research disciplines that include Cancer and Lyme disease. The research institute encourages scientific collaboration/partnerships with other research organizations in an effort to pioneer discovery and foster creative thinking. Research institute's leadership and management team are committed to promoting excellence in research by attracting highly qualified researchers, residents and physicians to the institution.

About Nuvance Health
Nuvance Health is a family of award-winning nonprofit hospitals and healthcare professionals in the Hudson Valley and western Connecticut. Nuvance Health combines highly skilled physicians, state-of-the-art facilities and technology, and compassionate caregivers dedicated to providing quality care across a variety of clinical areas, including Cardiovascular, Neurosciences, Oncology, Orthopedics, and Primary Care.

Nuvance Health has a network of convenient hospital and outpatient locations — Danbury Hospital, New Milford Hospital, Norwalk Hospital and Sharon Hospital in Connecticut, and Northern Dutchess Hospital, Putnam Hospital Center and Vassar Brothers Medical Center in New York — plus multiple primary and specialty care physician practice locations, including The Heart Center, a leading provider of cardiology care, and two urgent care offices. Non-acute care is offered through various affiliates, including the Thompson House for rehabilitation and skilled nursing services, and the Home Care organizations. For more information about Nuvance Health, visit our website.

Read the full story at https://www.prweb.com/releases/danbury_hospital_researchers_on_track_developing_tool_for_more_precise_diagnosis_of_gynecologic_cancers/prweb16723841.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Three New Health Systems Integrate Hyland Softwares OnBase with Meditech Hospital Information System
2. Lumalier Helps Hospitals Improve Infection Control Efforts with Real-time Disinfection Data from New iTRU-D Technology and Web Portal System
3. U.S. News & World Report Honors 7 SynCardia Certified Centers Among "Best Childrens Hospitals" for Cardiology and Heart Surgery
4. Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Groups Hospital Clients
5. Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Womens Health
6. Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes
7. Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital
8. Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals
9. Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart Wins Silver at Medical Design Excellence Awards
10. 14 Additional Hospitals Select CareFusion Pyxis ES Platform To Improve Medication Management Efficiency, Safety
11. RIC to Launch New Era in Rehabilitation Medicine, Break Ground July 1 on New $550 Million Research Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... ... The Harm Reduction Institute (HRI) as a part of the American Addiction ... and non-profit Intensive outpatient after care (IOP) , has officially launched its ... amongst members of the own community in Orange County, CA. , They hope ...
(Date:12/4/2019)... ... December 04, 2019 , ... Intelligent.com, a ... Top 17 Master's in Organizational Psychology Degree Programs for 2020. The comprehensive research ... the nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, ...
(Date:12/2/2019)... Kan. (PRWEB) , ... December 02, 2019 , ... ... XX, a nutritional supplement produced by Native Remedies aimed at supporting Women’s Fertility ... Unfortunately, Mother Nature makes conception harder for some women than for others. Factors ...
Breaking Medicine Technology:
(Date:12/5/2019)... ... 05, 2019 , ... It’s been an impactful year for ... people embrace, achieve, and maintain a healthy lifestyle to giving generously to communities ... mission of impacting world health, so it’s gratifying to look back on the ...
(Date:12/4/2019)... , ... December 04, 2019 , ... ... 2019 HREI Insights Awards™, the only national awards dedicated to recognizing excellence in ... The 2019 awards were presented in nine different categories during the GlobeSt Healthcare ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... solutions, has worked with EMD Serono, the North American branch of the healthcare ... . This site is designed to educate and inform patients, caregivers, the public, ...
(Date:11/30/2019)... ... November 29, 2019 , ... NJ Top Doc, Paul Kovatis, MD has been ... He has gained tremendous recognition and has received many awards over the past two ... aspects of lower extremity orthopedics. Through his training at Level I trauma centers, he ...
(Date:11/27/2019)... ... November 27, 2019 , ... The ... sense of smell has a far deeper reach. Aroma travels directly to the ... hugely beneficial effects on both consumers and workers. The human olfactory system is ...
Breaking Medicine News(10 mins):